David Brocklehurst

After more than 15 years with AstraZeneca, my current role as Vice President, Global Franchise Head of Gynaecological and Genitourinary Cancers allows me to continue supporting AstraZeneca’s ambition to push the boundaries of science, accelerate therapeutic innovation and transform patient lives by maximising access to those in urgent need of new therapy options.

With deep experience in Oncology, I am responsible for overseeing all aspects of AstraZeneca’s portfolio and pipeline in gynaecological and genitourinary cancers. I am passionate about improving outcomes for patients impacted by these diseases, which are difficult to treat and often impacted by stigma. I am especially proud of the work we do at AstraZeneca to address the critical gaps across the entire care pathway, from disease prevention and early diagnosis to treatment and long-term care.

I have held roles of increasing responsibility that include leading global teams for breast cancer and immuno-oncology. In my previous role as the Head of Oncology in the United Kingdom, I led the organisation’s initiatives around improving patient outcomes, including partnerships to help the National Health Service (NHS) to diagnose cancers, identify the right treatments earlier, and ensure that care pathways are optimised to improve outcomes. As Vice President, Oncology Business Unit Head for the Nordics, I was responsible for bringing all of AstraZeneca’s innovative oncology medicines to cancer patients in Denmark, Norway, Sweden, Finland and Iceland.